212 related articles for article (PubMed ID: 33329315)
1. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Chen Y; Guo Y; Chen H; Ma F
Front Neurol; 2020; 11():573264. PubMed ID: 33329315
[No Abstract] [Full Text] [Related]
2. Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling.
Wang Q; Wang Z; Li G; Zhang C; Bao Z; Wang Z; You G; Jiang T
Aging (Albany NY); 2018 Aug; 10(8):1977-1988. PubMed ID: 30115812
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
Front Oncol; 2019; 9():1433. PubMed ID: 31921684
[No Abstract] [Full Text] [Related]
5. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
Oncoimmunology; 2018; 7(6):e1434466. PubMed ID: 29872572
[No Abstract] [Full Text] [Related]
7. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
He Y; Ye Y; Tian W; Qiu H
Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
[No Abstract] [Full Text] [Related]
8. A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.
Liu Q; Wang K; Huang R; Tong X; Jiang T; Wang J; Yang P
J Cancer Res Clin Oncol; 2020 Mar; 146(3):579-591. PubMed ID: 32060643
[TBL] [Abstract][Full Text] [Related]
9. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma.
Zhang C; Yu R; Li Z; Song H; Zang D; Deng M; Fan Y; Liu Y; Zhang Y; Qu X
Cancer Manag Res; 2019; 11():4971-4984. PubMed ID: 31213913
[No Abstract] [Full Text] [Related]
12. Profiling pro-neural to mesenchymal transition identifies a lncRNA signature in glioma.
Liang Q; Guan G; Li X; Wei C; Wu J; Cheng P; Wu A; Cheng W
J Transl Med; 2020 Oct; 18(1):378. PubMed ID: 33028341
[TBL] [Abstract][Full Text] [Related]
13. Identification of N
Wang W; Li J; Lin F; Guo J; Zhao J
Neurosurg Rev; 2021 Feb; 44(1):463-470. PubMed ID: 31938968
[TBL] [Abstract][Full Text] [Related]
14. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
15. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
16. A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients.
Xiang Z; Chen X; Lv Q; Peng X
Front Genet; 2021; 12():697819. PubMed ID: 34408772
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma.
Zeng F; Wang K; Liu X; Zhao Z
Cell Commun Signal; 2020 Jan; 18(1):2. PubMed ID: 31907037
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
